IBD metabonomics predicts phenotype, disease course, and treatment response

Bjerrum, Jacob Tveiten; Wang, Yulan; Seidelin, Jakob Benedict; Nielsen, Ole Haagen

doi:10.1016/j.ebiom.2021.103551

Cited by 22 publications

(15 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dysbiosis is a known phenomenon in IBD, which influences the host metabolome. 30 Both dysbiosis and inflammation in IBD alter the regulation of several metabolic pathways like amino acids, SCFAs, lipids, BAs, carbohydrates, proteins, and others. These changes have been associated with IBD pathogenesis.…”

Section: Metabolome In Inflammatory Bowel Diseasementioning

confidence: 99%

Microbiome and metabolome in inflammatory bowel disease

Upadhyay

Desai

Ashavaid

et al. 2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic gastrointestinal disease of unknown etiology, involving complex interactions between the gut microbiome and host immune response. The microbial dysbiosis is well documented in IBD and significantly influences the host metabolic pathways. Thus, a metabolomic fingerprint resulting from the influence of gut dysbiosis in IBD could aid in assessing the disease activity. PubMed, Medline, Science Direct, and Web of Science were searched for studies exploring the association between microbiome and metabolome in IBD patients in the last 5 years. Additionally, references of cited original articles and reviews were further assessed for relevant work. We provide a literature overview of the recent metabolomic studies performed on patients with IBD. The findings report alterations in the metabolite levels of these patients. We also discuss the gut dysbiosis observed in IBD and its influence on host metabolic pathways such as lipids, amino acids, short-chain fatty acids, and others. IBD, being a chronic idiopathic disease, requires routine monitoring. The available non-invasive markers have their limitations. The metabolite changes account for both dysbiosis and its influence on the host's immune response and metabolism. A metabolome approach would thus facilitate the identification of surrogate metabolite markers reflecting the disease activity.

show abstract

Section: Metabolome In Inflammatory Bowel Diseasementioning

confidence: 99%

Microbiome and metabolome in inflammatory bowel disease

Upadhyay

Desai

Ashavaid

et al. 2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“… 33 Low plasma histidine level has also been suggested to be associated with poorer disease course. 34 – 36 …”

Section: Stratifying Ibd Patients At Diagnosis: Predictors Of Disease...mentioning

confidence: 99%

“…Metabolomics could also help in predicting the response to biotherapies. 36 In a prospective longitudinal cohort study enrolling 76 CD patients, Ding et al 264 demonstrated that a range of metabolic biomarkers may contribute to prediction of response to anti-TNF therapy in CD patients. Primary non-responders tended to have modification of serum lipids (higher level of ceramide and sphingomyelin) as well as serum and faecal bile acids changes (higher levels of circulating primary unconjugated bile acids as well as higher levels of bile acids conjugated to sulphate, taurine and glycine in faeces).…”

Section: Choosing the Appropriate Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Precision medicine and drug optimization in adult inflammatory bowel disease patients

Vieujean

Louis

2023

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) encompass two main entities including ulcerative colitis and Crohn’s disease. Although having a common global pathophysiological mechanism, IBD patients are characterized by a significant interindividual heterogeneity and may differ by their disease type, disease locations, disease behaviours, disease manifestations, disease course as well as treatment needs. Indeed, although the therapeutic armamentarium for these diseases has expanded rapidly in recent years, a proportion of patients remains with a suboptimal response to medical treatment due to primary non-response, secondary loss of response or intolerance to currently available drugs. Identifying, prior to treatment initiation, which patients are likely to respond to a specific drug would improve the disease management, avoid unnecessary side effects and reduce the healthcare expenses. Precision medicine classifies individuals into subpopulations according to clinical and molecular characteristics with the objective to tailor preventative and therapeutic interventions to the characteristics of each patient. Interventions would thus be performed only on those who will benefit, sparing side effects and expense for those who will not. This review aims to summarize clinical factors, biomarkers (genetic, transcriptomic, proteomic, metabolic, radiomic or from the microbiota) and tools that could predict disease progression to guide towards a step-up or top-down strategy. Predictive factors of response or non-response to treatment will then be reviewed, followed by a discussion about the optimal dose of drug required for patients. The time at which these treatments should be administered (or rather can be stopped in case of a deep remission or in the aftermath of a surgery) will also be addressed. IBD remain biologically complex, with multifactorial etiopathology, clinical heterogeneity as well as temporal and therapeutic variabilities, which makes precision medicine especially challenging in this area. Although applied for many years in oncology, it remains an unmet medical need in IBD.

show abstract

“…Moreover, metabolites participate in the pathogenesis of multiple diseases by acting as signaling molecules, immune modulators, endogenous toxins, and environmental sensors 10 . In particular, changes in tricarboxylic acid cycle intermediates, amino acid and lipid metabolism products, as well as oxidative metabolites are closely associated with energy metabolism, intestinal barrier, immune system, and disease activity in patients with IBD [13][14][15] . Additionally, emerging evidence suggests that alterations in metabolism are not only a feature of brosis but may also play an in uential role in its pathogenesis [16][17][18] .…”

Section: Introductionmentioning

confidence: 99%

Dynamic alterations in metabolomics and transcriptomics associated with intestinal fibrosis in a 2,4,6-trinitrobenzene sulfonic acid-induced murine model

Tian

Zhuang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background & aims:Intestinal fibrosis is a common and severe complication of inflammatory bowel disease without clear pathogenesis. Abnormal expression of host genes and metabolic perturbations might associate with the onset of intestinal fibrosis. In this study, we aimed to investigate the relationship between the development of intestinal fibrosis and the dynamic alterations in both fecal metabolites and host gene expression. Methods: We induced intestinal fibrosis in a murine model using 2,4,6-trinitrobenzene sulfonic acid (TNBS). TNBS-treated or control mice were sacrificed after 4 and 6 weeks of intervention; alterations incolonic genes and fecal metabolites were determined by transcriptomics and metabolomics, respectively. Differential, tendency, enrichment, and correlation analyses were performed to assess the relationship between host genes and fecal metabolites. Results: RNA-sequencing analysis revealed that 679 differential genes with enduring changes were mainly enriched in immune response-related signaling pathways and metabolism-related biological processes. Among them, 15 lipid metabolism-related genes were closely related to the development of intestinal fibrosis. Moreover, the fecal metabolic profile was significantly altered during intestinal fibrosis development, especially the lipid metabolites. Particularly, dynamic perturbations in lipids were strongly associated with alterations in lipid metabolism-related genes expression. Additionally, six dynamically altered metabolites might serve as biomarkers to identify colitis-related intestinal fibrosis in the murine model. Conclusions: Intestinal fibrosis in colitis mice might be related to dynamic changes in gene expression and metabolites. These findings could provide new insights into the pathogenesis of intestinal fibrosis.

show abstract

IBD metabonomics predicts phenotype, disease course, and treatment response

Cited by 22 publications

References 76 publications

Microbiome and metabolome in inflammatory bowel disease

Microbiome and metabolome in inflammatory bowel disease

Precision medicine and drug optimization in adult inflammatory bowel disease patients

Dynamic alterations in metabolomics and transcriptomics associated with intestinal fibrosis in a 2,4,6-trinitrobenzene sulfonic acid-induced murine model

Contact Info

Product

Resources

About